Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients.
Hemodialysis patients have an elevated genomic damage in peripheral blood lymphocytes (PBLs) and an increased cancer incidence, possibly due to accumulation of uremic toxins like advanced glycation end products (AGEs). Because the vitamin B1 prodrug benfotiamine reduces AGE levels in experimental diabetes, and dialysis patients often suffer from vitamin B1 deficiency, we conducted two consecutive studies supplementing hemodialysis patients with benfotiamine. In both studies, genomic damage was measured as micronucleus frequency of PBLs before and at three time-points after initiation of benfotiamine supplementation. AGE-associated fluorescence in plasma, and in the second study additionally, the antioxidative capacity of plasma was analyzed. Benfotiamine significantly lowered the genomic damage of PBLs in hemodialysis patients of both studies independent of changes in plasma AGE levels. The second study gave a hint to the mechanism, as the antioxidative capacity of the plasma of the treated patients clearly increased, which might ameliorate the DNA damage.
Department of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany. nicole.schupp@toxi.uni-wuerzburg.de
Nicole
N
Schupp
Eva Maria
EM
Dette
Ursula
U
Schmid
Udo
U
Bahner
Michaela
M
Winkler
August
A
Heidland
Helga
H
Stopper
D000368:Aged; D016587:Antimutagenic Agents; D002469:Cell Separation; D002478:Cells, Cultured; D004249:DNA Damage; D003928:Diabetic Nephropathies / Q000235:genetics / Q000628:therapy; D005260:Female; D005290:Ferric Compounds / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000235:genetics / Q000628:therapy; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D015162:Micronucleus Tests; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D010084:Oxidation-Reduction; D010865:Pilot Projects; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects*; D016037:Single-Blind Method; D013831:Thiamine / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D014174:Transketolase / Q000097:blood
D016587:Antimutagenic Agents; D005290:Ferric Compounds; D017127:Glycation End Products, Advanced; D014174:Transketolase; D013831:Thiamine; C013835:benphothiamine